25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Moleculin Biotech Inc
Buy, Hold or Sell?

Let's analyze Moleculin together

I guess you are interested in Moleculin Biotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Moleculin Biotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Moleculin Biotech Inc

I send you an email if I find something interesting about Moleculin Biotech Inc.

1. Quick Overview

1.1. Quick analysis of Moleculin (30 sec.)










1.2. What can you expect buying and holding a share of Moleculin? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.01
Expected worth in 1 year
$-7.68
How sure are you?
24.3%

+ What do you gain per year?

Total Gains per Share
$-9.69
Return On Investment
-417.7%

For what price can you sell your share?

Current Price per Share
$2.32
Expected price per share
$2.3 - $4.707
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Moleculin (5 min.)




Live pricePrice per Share (EOD)
$2.32
Intrinsic Value Per Share
$-112.93 - $-133.54
Total Value Per Share
$-110.91 - $-131.52

2.2. Growth of Moleculin (5 min.)




Is Moleculin growing?

Current yearPrevious yearGrowGrow %
How rich?$7.4m$43.3m-$25.1m-137.9%

How much money is Moleculin making?

Current yearPrevious yearGrowGrow %
Making money-$7.5m-$6.1m-$1.3m-18.3%
Net Profit Margin-938.4%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Moleculin (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#650 / 944

Most Revenue
#624 / 944

Most Profit
#500 / 944

Most Efficient
#691 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Moleculin?

Welcome investor! Moleculin's management wants to use your money to grow the business. In return you get a share of Moleculin.

First you should know what it really means to hold a share of Moleculin. And how you can make/lose money.

Speculation

The Price per Share of Moleculin is $2.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Moleculin.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Moleculin, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.01. Based on the TTM, the Book Value Change Per Share is $-2.42 per quarter. Based on the YOY, the Book Value Change Per Share is $2.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Moleculin.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.85-122.9%-2.34-100.9%-1.96-84.5%-1.05-45.1%-0.96-41.2%
Usd Book Value Change Per Share-3.88-167.4%-2.42-104.4%2.42104.1%-0.02-1.1%0.052.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-3.88-167.4%-2.42-104.4%2.42104.1%-0.02-1.1%0.052.3%
Usd Price Per Share2.84-3.28-0.76-1.86-1.85-
Price to Earnings Ratio-0.25--0.45--0.10--1.50--1.33-
Price-to-Total Gains Ratio-0.73--1.92--0.24--2.02--2.16-
Price to Book Ratio1.41-0.73-0.05-0.56-0.48-
Price-to-Total Gains Ratio-0.73--1.92--0.24--2.02--2.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.32
Number of shares431
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-2.42-0.02
Usd Total Gains Per Share-2.42-0.02
Gains per Quarter (431 shares)-1,044.28-10.57
Gains per Year (431 shares)-4,177.11-42.29
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4177-41870-42-52
20-8354-83640-85-94
30-12531-125410-127-136
40-16708-167180-169-178
50-20886-208950-211-220
60-25063-250720-254-262
70-29240-292490-296-304
80-33417-334260-338-346
90-37594-376030-381-388
100-41771-417800-423-430

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.037.00.00.0%0.037.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%9.027.01.024.3%9.027.01.024.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%9.027.01.024.3%9.027.01.024.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Moleculin Biotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.884-2.423-38%2.416-261%-0.025-99%0.054-7238%
Book Value Per Share--2.0145.947-66%14.431-86%5.508-63%4.665-57%
Current Ratio--2.0752.956-30%7.442-72%9.139-77%6.409-68%
Debt To Asset Ratio--0.6800.401+69%0.113+501%0.241+182%1.122-39%
Debt To Equity Ratio--2.1280.867+146%0.128+1560%0.424+402%0.328+549%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--4038549.52014217574.370-72%31101162.493-87%55569142.239-93%38095566.901-89%
Eps---2.852-2.342-18%-1.960-31%-1.046-63%-0.957-66%
Ev To Ebitda Ratio---0.142-0.509+258%-1.107+679%-0.737+418%-1.122+690%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---1.646-1.924+17%-2.170+32%-1.020-38%-0.791-52%
Free Cash Flow To Equity Per Share---0.391-1.612+312%-2.171+455%-0.536+37%-0.226-42%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%46.224-98%
Intrinsic Value_10Y_max---133.538--------
Intrinsic Value_10Y_min---112.927--------
Intrinsic Value_1Y_max---6.865--------
Intrinsic Value_1Y_min---6.739--------
Intrinsic Value_3Y_max---25.593--------
Intrinsic Value_3Y_min---24.333--------
Intrinsic Value_5Y_max---50.309--------
Intrinsic Value_5Y_min---46.268--------
Market Cap6964408.000-51%10548549.52010358324.370+2%2271162.493+364%26966842.239-61%17671065.125-40%
Net Profit Margin----9.3840%-0%-15215.9840%-8233.4630%
Operating Margin----9.6030%-0%-25983.4060%-14052.3040%
Operating Ratio---9.603-100%-0%20963.284-100%11338.724-100%
Pb Ratio1.152-22%1.4100.732+93%0.051+2669%0.563+150%0.485+191%
Pe Ratio-0.203+18%-0.249-0.454+82%-0.096-61%-1.499+502%-1.329+434%
Price Per Share2.320-22%2.8403.282-13%0.757+275%1.858+53%1.850+53%
Price To Free Cash Flow Ratio-0.352+18%-0.431-0.413-4%-0.089-79%-1.347+212%-1.170+171%
Price To Total Gains Ratio-0.597+18%-0.731-1.923+163%-0.236-68%-2.018+176%-2.161+196%
Quick Ratio--1.6822.542-34%6.899-76%8.601-80%6.021-72%
Return On Assets---0.453-0.263-42%-0.128-72%-0.139-69%-1.940+328%
Return On Equity---1.416-0.571-60%-0.145-90%-0.237-83%-0.186-87%
Total Gains Per Share---3.884-2.423-38%2.416-261%-0.025-99%0.054-7238%
Usd Book Value--7479000.00018211000.000-59%43320250.000-83%42787650.000-83%29590200.838-75%
Usd Book Value Change Per Share---3.884-2.423-38%2.416-261%-0.025-99%0.054-7238%
Usd Book Value Per Share--2.0145.947-66%14.431-86%5.508-63%4.665-57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--4038549.52014217574.370-72%31101162.493-87%55569142.239-93%38095566.901-89%
Usd Eps---2.852-2.342-18%-1.960-31%-1.046-63%-0.957-66%
Usd Free Cash Flow---6113000.000-6070000.000-1%-6515000.000+7%-5629700.000-8%-4046686.261-34%
Usd Free Cash Flow Per Share---1.646-1.924+17%-2.170+32%-1.020-38%-0.791-52%
Usd Free Cash Flow To Equity Per Share---0.391-1.612+312%-2.171+455%-0.536+37%-0.226-42%
Usd Market Cap6964408.000-51%10548549.52010358324.370+2%2271162.493+364%26966842.239-61%17671065.125-40%
Usd Price Per Share2.320-22%2.8403.282-13%0.757+275%1.858+53%1.850+53%
Usd Profit---10592000.000-7537500.000-29%-6155000.000-42%-5691500.000-46%-4113890.351-61%
Usd Revenue---203000.000-100%-0%40606.450-100%22192.676-100%
Usd Total Gains Per Share---3.884-2.423-38%2.416-261%-0.025-99%0.054-7238%
 EOD+3 -5MRQTTM+11 -23YOY+11 -215Y+6 -2810Y+6 -29

3.3 Fundamental Score

Let's check the fundamental score of Moleculin Biotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.203
Price to Book Ratio (EOD)Between0-11.152
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.682
Current Ratio (MRQ)Greater than12.075
Debt to Asset Ratio (MRQ)Less than10.680
Debt to Equity Ratio (MRQ)Less than12.128
Return on Equity (MRQ)Greater than0.15-1.416
Return on Assets (MRQ)Greater than0.05-0.453
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Moleculin Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.052
Ma 20Greater thanMa 502.602
Ma 50Greater thanMa 1002.549
Ma 100Greater thanMa 2002.543
OpenGreater thanClose2.580
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Fundamental data was last updated by Penke on 2024-12-06 01:00:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Moleculin earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Moleculin to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Moleculin Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-938.4%+938.4%
TTM-938.4%YOY--938.4%
TTM-938.4%5Y-1,521,598.4%+1,520,660.1%
5Y-1,521,598.4%10Y-823,346.3%-698,252.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.6%+108.6%
TTM-938.4%-221.4%-717.0%
YOY--207.4%+207.4%
5Y-1,521,598.4%-346.2%-1,521,252.2%
10Y-823,346.3%-470.4%-822,875.9%
4.3.1.2. Return on Assets

Shows how efficient Moleculin is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Moleculin to the Biotechnology industry mean.
  • -45.3% Return on Assets means that Moleculin generated $-0.45 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Moleculin Biotech Inc:

  • The MRQ is -45.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -26.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.3%TTM-26.3%-19.0%
TTM-26.3%YOY-12.8%-13.5%
TTM-26.3%5Y-13.9%-12.4%
5Y-13.9%10Y-194.0%+180.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.3%-11.6%-33.7%
TTM-26.3%-12.0%-14.3%
YOY-12.8%-11.2%-1.6%
5Y-13.9%-12.6%-1.3%
10Y-194.0%-14.1%-179.9%
4.3.1.3. Return on Equity

Shows how efficient Moleculin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Moleculin to the Biotechnology industry mean.
  • -141.6% Return on Equity means Moleculin generated $-1.42 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Moleculin Biotech Inc:

  • The MRQ is -141.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -57.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-141.6%TTM-57.1%-84.5%
TTM-57.1%YOY-14.5%-42.7%
TTM-57.1%5Y-23.7%-33.4%
5Y-23.7%10Y-18.6%-5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-141.6%-14.5%-127.1%
TTM-57.1%-16.0%-41.1%
YOY-14.5%-14.6%+0.1%
5Y-23.7%-18.5%-5.2%
10Y-18.6%-19.2%+0.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Moleculin Biotech Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Moleculin is operating .

  • Measures how much profit Moleculin makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Moleculin to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Moleculin Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-960.3%+960.3%
TTM-960.3%YOY--960.3%
TTM-960.3%5Y-2,598,340.6%+2,597,380.3%
5Y-2,598,340.6%10Y-1,405,230.4%-1,193,110.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM-960.3%-316.8%-643.5%
YOY--215.6%+215.6%
5Y-2,598,340.6%-376.1%-2,597,964.5%
10Y-1,405,230.4%-480.3%-1,404,750.1%
4.3.2.2. Operating Ratio

Measures how efficient Moleculin is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM9.603-9.603
TTM9.603YOY-+9.603
TTM9.6035Y20,963.284-20,953.681
5Y20,963.28410Y11,338.724+9,624.560
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM9.6033.198+6.405
YOY-3.247-3.247
5Y20,963.2844.651+20,958.633
10Y11,338.7246.419+11,332.305
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Moleculin Biotech Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Moleculin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.08 means the company has $2.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 2.075. The company is able to pay all its short-term debts. +1
  • The TTM is 2.956. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.075TTM2.956-0.881
TTM2.956YOY7.442-4.486
TTM2.9565Y9.139-6.183
5Y9.13910Y6.409+2.730
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0753.586-1.511
TTM2.9563.869-0.913
YOY7.4424.644+2.798
5Y9.1395.971+3.168
10Y6.4096.240+0.169
4.4.3.2. Quick Ratio

Measures if Moleculin is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Moleculin to the Biotechnology industry mean.
  • A Quick Ratio of 1.68 means the company can pay off $1.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 1.682. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.542. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.682TTM2.542-0.861
TTM2.542YOY6.899-4.356
TTM2.5425Y8.601-6.058
5Y8.60110Y6.021+2.580
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6823.093-1.411
TTM2.5423.392-0.850
YOY6.8994.304+2.595
5Y8.6015.953+2.648
10Y6.0216.435-0.414
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Moleculin Biotech Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Moleculin assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Moleculin to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.68 means that Moleculin assets are financed with 68.0% credit (debt) and the remaining percentage (100% - 68.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 0.680. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.401. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.680TTM0.401+0.279
TTM0.401YOY0.113+0.288
TTM0.4015Y0.241+0.160
5Y0.24110Y1.122-0.881
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6800.346+0.334
TTM0.4010.347+0.054
YOY0.1130.313-0.200
5Y0.2410.365-0.124
10Y1.1220.383+0.739
4.5.4.2. Debt to Equity Ratio

Measures if Moleculin is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Moleculin to the Biotechnology industry mean.
  • A Debt to Equity ratio of 212.8% means that company has $2.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 2.128. The company is just not able to pay all its debts with equity.
  • The TTM is 0.867. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ2.128TTM0.867+1.261
TTM0.867YOY0.128+0.739
TTM0.8675Y0.424+0.443
5Y0.42410Y0.328+0.096
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1280.393+1.735
TTM0.8670.432+0.435
YOY0.1280.388-0.260
5Y0.4240.455-0.031
10Y0.3280.498-0.170
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Moleculin generates.

  • Above 15 is considered overpriced but always compare Moleculin to the Biotechnology industry mean.
  • A PE ratio of -0.25 means the investor is paying $-0.25 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Moleculin Biotech Inc:

  • The EOD is -0.203. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.249. Based on the earnings, the company is expensive. -2
  • The TTM is -0.454. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.203MRQ-0.249+0.046
MRQ-0.249TTM-0.454+0.205
TTM-0.454YOY-0.096-0.358
TTM-0.4545Y-1.499+1.045
5Y-1.49910Y-1.329-0.171
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.203-2.180+1.977
MRQ-0.249-2.507+2.258
TTM-0.454-3.153+2.699
YOY-0.096-3.242+3.146
5Y-1.499-5.992+4.493
10Y-1.329-6.690+5.361
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Moleculin Biotech Inc:

  • The EOD is -0.352. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.431. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.413. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.352MRQ-0.431+0.079
MRQ-0.431TTM-0.413-0.018
TTM-0.413YOY-0.089-0.324
TTM-0.4135Y-1.347+0.934
5Y-1.34710Y-1.170-0.177
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.352-2.879+2.527
MRQ-0.431-3.276+2.845
TTM-0.413-3.669+3.256
YOY-0.089-4.485+4.396
5Y-1.347-8.015+6.668
10Y-1.170-9.197+8.027
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Moleculin is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.41 means the investor is paying $1.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Moleculin Biotech Inc:

  • The EOD is 1.152. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.410. Based on the equity, the company is underpriced. +1
  • The TTM is 0.732. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.152MRQ1.410-0.258
MRQ1.410TTM0.732+0.678
TTM0.732YOY0.051+0.681
TTM0.7325Y0.563+0.169
5Y0.56310Y0.485+0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1521.964-0.812
MRQ1.4102.056-0.646
TTM0.7322.388-1.656
YOY0.0512.460-2.409
5Y0.5633.697-3.134
10Y0.4854.324-3.839
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Moleculin Biotech Inc.

4.8.1. Institutions holding Moleculin Biotech Inc

Institutions are holding 15.342% of the shares of Moleculin Biotech Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Armistice Capital, LLC9.66060.013229000013400085.8974
2024-09-30Vanguard Group Inc2.3786071403-13015-15.4173
2024-09-30LPL Financial Corp1.20270.00013610323496.9592
2024-09-30Geode Capital Management, LLC0.7268021818206210.4373
2024-06-30BlackRock Inc0.415601247520.016
2024-09-30Renaissance Technologies Corp0.36630.000110996109960
2024-09-30BB&T Corp.0.34980.000110500105000
2024-09-30ATTICUS WEALTH MANAGEMENT, LLC0.11110.003333400
2024-09-30Tower Research Capital LLC0.06030.00011811-184-9.2231
2024-09-30Newbridge Financial Services Group, Inc.0.04550.0014136700
2024-09-30Morgan Stanley - Brokerage Accounts0.0150449-403-47.3005
2024-06-30Sandy Spring Bank0.00308900
2024-09-30CVA Family Office, LLC0.001103400
2024-06-30Bank of America Corp0.000902821300
2024-06-30Advisor Group Holdings, Inc.0.0008023-42-64.6154
2024-09-30North Star Investment Management Corp0.000601700
2024-06-30Royal Bank of Canada0.000301000
2024-09-30JPMorgan Chase & Co001-5-83.3333
2024-06-30Wells Fargo & Co000-19-100
2024-06-30Goss Wealth Management LLC000-1-100
Total 15.3390.018460458+146261+31.8%

4.9.2. Funds holding Moleculin Biotech Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.00980.00013031400
2024-10-31Vanguard Total Stock Mkt Idx Inv0.5616016859-23609-58.3399
2024-09-30Fidelity Extended Market Index0.50370.000115121289923.7195
2024-09-30Fidelity Series Total Market Index0.08050241800
2024-09-30Fidelity Total Market Index0.06850205500
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.05810.0001174300
2024-09-30NT Ext Equity Mkt Idx Fd - L0.05790.0001173800
2024-09-30Northern Trust Extended Eq Market Idx0.05790.0001173800
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.04680.0001140440.2857
2024-09-30Spartan Total Market Index Pool E0.03730112100
2024-09-30Fidelity Nasdaq Composite Index0.03460103900
2024-10-31State St US Extended Mkt Indx NL Cl C0.0260.000178000
2024-10-31Vanguard U.S. Eq Idx £ Acc0.0207062100
2024-06-30SSgA U.S. Total Market Index Strategy0.010703209542.2222
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00890.000126800
2024-10-31State St US Ttl Mkt Indx SL Cl I0.0073022000
2024-09-30Northern Trust Wilshire 50000.002808300
2024-09-30Spartan Extended Market Index Pool E0.0016049490
2024-09-30Fidelity U.S. Equity Index Ins Trust0.000501500
Total 2.59520.000877906-20562-26.4%

5.3. Insider Transactions

Insiders are holding 3.34% of the shares of Moleculin Biotech Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-26Jonathan P FosterBUY193210.35
2023-12-26Robert E GeorgeBUY96610.35
2023-12-26Walter V KlempBUY1256010.35
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Accumulated Other Comprehensive Income  -3-6-9-9-188-10144



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets23,394
Total Liabilities15,915
Total Stockholder Equity7,479
 As reported
Total Liabilities 15,915
Total Stockholder Equity+ 7,479
Total Assets = 23,394

Assets

Total Assets23,394
Total Current Assets11,606
Long-term Assets11,788
Total Current Assets
Cash And Cash Equivalents 9,405
Other Current Assets 2,201
Total Current Assets  (as reported)11,606
Total Current Assets  (calculated)11,606
+/-0
Long-term Assets
Property Plant Equipment 640
Intangible Assets 11,148
Long-term Assets  (as reported)11,788
Long-term Assets  (calculated)11,788
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,593
Long-term Liabilities10,322
Total Stockholder Equity7,479
Total Current Liabilities
Short-term Debt 116
Accounts payable 2,550
Other Current Liabilities 2,927
Total Current Liabilities  (as reported)5,593
Total Current Liabilities  (calculated)5,593
+/-0
Long-term Liabilities
Capital Lease Obligations 506
Long-term Liabilities  (as reported)10,322
Long-term Liabilities  (calculated)506
+/- 9,816
Total Stockholder Equity
Common Stock3
Retained Earnings -151,485
Accumulated Other Comprehensive Income 4
Other Stockholders Equity 158,957
Total Stockholder Equity (as reported)7,479
Total Stockholder Equity (calculated)7,479
+/-0
Other
Capital Stock3
Cash and Short Term Investments 9,405
Common Stock Shares Outstanding 3,714
Liabilities and Stockholders Equity 23,394
Net Debt -8,899
Net Invested Capital 7,479
Net Working Capital 6,013
Property Plant and Equipment Gross 640
Short Long Term Debt Total 506



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
> Total Assets 
110
28
290
19,233
17,574
16,393
16,393
21,249
20,633
19,483
24,929
24,066
20,899
19,585
21,298
31,854
30,398
25,235
25,472
31,380
27,144
29,031
99,784
93,534
88,702
84,090
78,801
73,255
65,372
57,422
51,062
47,115
39,523
38,217
30,845
25,575
23,394
23,39425,57530,84538,21739,52347,11551,06257,42265,37273,25578,80184,09088,70293,53499,78429,03127,14431,38025,47225,23530,39831,85421,29819,58520,89924,06624,92919,48320,63321,24916,39316,39317,57419,23329028110
   > Total Current Assets 
110
28
290
7,560
6,429
5,222
5,222
10,081
9,463
8,302
13,748
12,892
9,360
7,974
9,613
20,202
18,586
13,484
13,787
19,749
15,250
17,198
88,019
81,836
77,070
72,497
67,260
61,322
53,493
45,596
39,289
35,380
27,603
26,273
18,957
13,731
11,606
11,60613,73118,95726,27327,60335,38039,28945,59653,49361,32267,26072,49777,07081,83688,01917,19815,25019,74913,78713,48418,58620,2029,6137,9749,36012,89213,7488,3029,46310,0815,2225,2226,4297,56029028110
       Cash And Cash Equivalents 
87
28
260
7,245
6,184
5,007
5,007
9,272
8,736
7,714
13,114
11,722
8,600
7,134
8,782
18,695
15,409
10,735
11,649
16,734
12,795
15,173
86,293
79,506
75,178
70,903
66,104
57,999
50,392
43,145
37,265
32,172
24,579
23,550
16,824
10,845
9,405
9,40510,84516,82423,55024,57932,17237,26543,14550,39257,99966,10470,90375,17879,50686,29315,17312,79516,73411,64910,73515,40918,6958,7827,1348,60011,72213,1147,7148,7369,2725,0075,0076,1847,2452602887
       Net Receivables 
0
0
30
0
0
0
0
0
0
0
0
0
0
0
0
0
316
11
1
13
6
1
1
0
0
45
27
33
10
22
0
12
0
99
99
9
0
09999901202210332745001161311131600000000000003000
       Other Current Assets 
23
0
30
315
245
215
215
809
727
588
634
1,170
760
840
831
1,507
307
529
615
436
257
164
1,726
2,330
1,892
1,549
1,129
3,323
3,091
2,451
2,024
3,208
3,024
2,624
2,133
2,420
2,201
2,2012,4202,1332,6243,0243,2082,0242,4513,0913,3231,1291,5491,8922,3301,7261642574366155293071,5078318407601,17063458872780921521524531530023
   > Long-term Assets 
0
0
0
11,674
11,145
11,171
11,171
11,168
11,170
11,181
11,181
11,174
11,539
11,611
11,685
11,652
11,812
11,751
11,685
11,631
11,894
11,833
11,765
11,698
11,632
11,593
11,541
11,933
11,879
11,826
11,773
11,735
11,920
11,944
11,888
11,844
11,788
11,78811,84411,88811,94411,92011,73511,77311,82611,87911,93311,54111,59311,63211,69811,76511,83311,89411,63111,68511,75111,81211,65211,68511,61111,53911,17411,18111,18111,17011,16811,17111,17111,14511,674000
       Property Plant Equipment 
0
0
0
7
16
23
23
20
22
33
33
26
391
463
537
504
664
603
537
483
746
685
617
550
484
445
393
785
731
678
625
587
772
796
740
696
640
64069674079677258762567873178539344548455061768574648353760366450453746339126333322202323167000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,137
11,137
0
0
0011,13711,137000000000000000000000000000000000
       Intangible Assets 
0
0
0
11,666
11,129
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11
11,148
11,148
11,148
11,14811,14811,1481111,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,12911,666000
       Other Assets 
0
0
30
11,173
11,129
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
0
0
0
0
0
0
0
0
685
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000006850000000011,14811,14811,14811,14811,14811,14811,14811,14811,12911,1733000
> Total Liabilities 
333
773
978
2,003
1,330
1,433
1,433
1,980
1,982
2,365
4,359
7,318
5,931
5,313
6,616
9,762
11,423
9,664
10,180
15,751
12,677
11,271
11,268
8,834
7,443
5,097
6,136
6,896
6,955
5,231
5,378
6,847
4,385
12,144
9,258
7,870
15,915
15,9157,8709,25812,1444,3856,8475,3785,2316,9556,8966,1365,0977,4438,83411,26811,27112,67715,75110,1809,66411,4239,7626,6165,3135,9317,3184,3592,3651,9821,9801,4331,4331,3302,003978773333
   > Total Current Liabilities 
333
773
978
1,403
1,280
1,345
1,345
1,830
1,832
2,215
1,799
4,116
3,129
3,878
6,436
9,591
11,119
3,570
3,235
3,739
3,438
2,920
4,578
3,350
3,656
3,622
4,834
5,859
6,362
4,819
5,032
6,554
3,888
6,815
5,408
5,746
5,593
5,5935,7465,4086,8153,8886,5545,0324,8196,3625,8594,8343,6223,6563,3504,5782,9203,4383,7393,2353,57011,1199,5916,4363,8783,1294,1161,7992,2151,8321,8301,3451,3451,2801,403978773333
       Short-term Debt 
250
450
615
432
298
296
296
1,185
743
503
463
451
369
180
33
35
100
103
107
110
114
118
122
126
115
96
77
98
112
116
0
0
88
100
109
112
116
116112109100880011611298779611512612211811411010710310035331803694514635037431,185296296298432615450250
       Short Long Term Debt 
0
450
0
0
0
296
108
0
0
0
0
0
0
0
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000003300000001082960004500
       Accounts payable 
63
323
363
721
945
1,049
399
645
1,089
810
570
1,676
785
1,246
2,799
1,257
3,188
2,153
1,206
1,918
1,343
1,129
1,928
1,505
1,390
1,364
2,224
3,184
3,568
2,095
1,939
4,136
2,008
2,498
2,104
2,833
2,550
2,5502,8332,1042,4982,0084,1361,9392,0953,5683,1842,2241,3641,3901,5051,9281,1291,3431,9181,2062,1533,1881,2572,7991,2467851,6765708101,0896453991,04994572136332363
       Other Current Liabilities 
20
88
363
250
38
88
650
1,185
743
1,405
1,229
2,440
2,344
2,632
2,386
6,944
6,820
164
79
75
1,981
1,673
2,528
1,719
2,151
2,162
2,533
2,675
2,682
2,608
3,093
2,418
1,880
4,217
3,195
2,801
2,927
2,9272,8013,1954,2171,8802,4183,0932,6082,6822,6752,5332,1622,1511,7192,5281,6731,98175791646,8206,9442,3862,6322,3442,4401,2291,4057431,18565088382503638820
   > Long-term Liabilities 
0
0
615
600
50
0
88
150
150
150
2,560
3,202
2,802
1,435
180
171
304
6,094
6,945
12,012
9,239
8,351
6,690
5,484
3,787
1,475
1,302
1,037
593
412
346
293
497
5,329
3,850
2,124
10,322
10,3222,1243,8505,3294972933464125931,0371,3021,4753,7875,4846,6908,3519,23912,0126,9456,0943041711801,4352,8023,2022,5601501501508805060061500
       Other Liabilities 
0
0
0
0
50
88
1,971
150
150
150
2,560
3,202
2,802
1,435
0
0
0
5,818
6,697
11,792
9,049
8,192
6,563
5,390
3,712
1,412
1,252
649
228
0
0
2
0
0
0
0
0
000002002286491,2521,4123,7125,3906,5638,1929,04911,7926,6975,8180001,4352,8023,2022,5601501501501,97188500000
       Deferred Long Term Liability 
0
0
0
0
0
0
1,846
0
0
150
2,410
3,202
2,802
1,435
0
0
0
5,818
6,697
11,792
9,049
0
6,563
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000006,56309,04911,7926,6975,8180001,4352,8023,2022,410150001,846000000
> Total Stockholder Equity
-222
-745
-688
17,231
16,244
14,960
14,960
19,269
18,651
17,118
20,570
16,748
14,968
14,272
14,682
22,092
18,975
15,571
15,292
15,629
14,467
17,760
88,516
84,700
81,259
78,993
72,665
66,359
58,417
52,191
45,684
40,268
35,138
26,073
21,587
17,705
7,479
7,47917,70521,58726,07335,13840,26845,68452,19158,41766,35972,66578,99381,25984,70088,51617,76014,46715,62915,29215,57118,97522,09214,68214,27214,96816,74820,57017,11818,65119,26914,96014,96016,24417,231-688-745-222
   Common Stock
7
7
7
11
12
12
12
21
21
21
26
27
27
29
34
45
46
46
53
60
62
69
28
29
29
29
29
29
29
29
30
30
30
33
2
3
3
33233303030292929292929292869626053464645342927272621212112121211777
   Retained Earnings -151,485-140,893-136,574-131,604-121,335-115,726-109,750-101,835-95,065-86,454-79,677-72,810-69,984-65,605-61,361-56,916-54,277-50,882-40,770-39,561-35,763-31,618-30,397-26,356-23,571-21,532-16,407-14,480-11,295-8,429-4,675-4,675-3,251-2,076-1,081-748-224
   Accumulated Other Comprehensive Income 
-5
0
-3
-3
-3
-6
0
-34
0
0
-32
6
21
35
24
22
19
31
-2
23
33
65
61
55
39
41
53
22
3
12
8
7
-3
-9
-18
-10
4
4-10-18-9-378123225341395561653323-23119222435216-3200-340-6-3-3-30-5
   Capital Surplus 
0
0
388
19,299
19,486
19,623
21,128
27,711
29,925
31,577
36,951
38,247
38,491
40,564
45,021
53,643
54,673
55,055
56,011
66,428
68,649
74,671
149,788
150,231
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000150,231149,78874,67168,64966,42856,01155,05554,67353,64345,02140,56438,49138,24736,95131,57729,92527,71121,12819,62319,48619,29938800
   Treasury Stock0000000000000000000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-127
Gross Profit-127-127
 
Operating Income (+$)
Gross Profit-127
Operating Expense-29,631
Operating Income-29,631-29,758
 
Operating Expense (+$)
Research Development19,487
Selling General Administrative10,017
Selling And Marketing Expenses10,007
Operating Expense29,63139,511
 
Net Interest Income (+$)
Interest Income1,232
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,232
 
Pretax Income (+$)
Operating Income-29,631
Net Interest Income1,232
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-29,769-29,493
EBIT - interestExpense = -29,631
-29,769
-29,769
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-29,631-29,769
Earnings Before Interest and Taxes (EBITDA)-29,504
 
After tax Income (+$)
Income Before Tax-29,769
Tax Provision-0
Net Income From Continuing Ops-26,270-29,769
Net Income-29,769
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses29,631
Total Other Income/Expenses Net-138-1,232
 

Technical Analysis of Moleculin
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Moleculin. The general trend of Moleculin is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Moleculin's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Moleculin Biotech Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.215 < 3.33 < 4.707.

The bearish price targets are: 2.3 > 2.3 > 2.3.

Tweet this
Moleculin Biotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Moleculin Biotech Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Moleculin Biotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Moleculin Biotech Inc. The current macd is -0.0371503.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Moleculin price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Moleculin. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Moleculin price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Moleculin Biotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartMoleculin Biotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Moleculin Biotech Inc. The current adx is 20.60.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Moleculin shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Moleculin Biotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Moleculin Biotech Inc. The current sar is 3.1.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Moleculin Biotech Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Moleculin Biotech Inc. The current rsi is 43.05. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Moleculin Biotech Inc Daily Relative Strength Index (RSI) ChartMoleculin Biotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Moleculin Biotech Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Moleculin price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Moleculin Biotech Inc Daily Stochastic Oscillator ChartMoleculin Biotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Moleculin Biotech Inc. The current cci is -175.98525204.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Moleculin Biotech Inc Daily Commodity Channel Index (CCI) ChartMoleculin Biotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Moleculin Biotech Inc. The current cmo is -19.6023014.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Moleculin Biotech Inc Daily Chande Momentum Oscillator (CMO) ChartMoleculin Biotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Moleculin Biotech Inc. The current willr is -97.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Moleculin Biotech Inc Daily Williams %R ChartMoleculin Biotech Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Moleculin Biotech Inc.

Moleculin Biotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Moleculin Biotech Inc. The current atr is 0.26683108.

Moleculin Biotech Inc Daily Average True Range (ATR) ChartMoleculin Biotech Inc Daily Average True Range (ATR) Chart